232 results on '"Pérez-Miralles, Francisco"'
Search Results
2. Renal function’s impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis
3. Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis
4. Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma
5. Correction to: Dynamic 18 F-FDG PET to detect differences among patients with progressive and relapsing multiple sclerosis: a pilot study
6. Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
7. Eculizumab for a catastrophic relapse in NMOSD: case report
8. Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?
9. Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm
10. Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study
11. Oligoclonal M bands unveil occult inflammation in multiple sclerosis
12. Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study
13. Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels.
14. Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report.
15. Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients.
16. Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks
17. Cognitive impairment in multiple sclerosis: diagnosis and monitoring
18. Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study)
19. Adding brain volume measures into response criteria in multiple sclerosis: the Río-4 score
20. Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks
21. Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.
22. Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma
23. SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry
24. Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe
25. Reader response: Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis
26. Eculizumab for a catastrophic relapse in NMOSD: case report
27. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs
28. Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience
29. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
30. Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann–Pick type C disease: review of initial published cases
31. Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks
32. Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis
33. Neuronal antigens recognized by cerebrospinal fluid IgM in multiple sclerosis
34. Cognitive performance and health-related quality of life in patients with neuromyelitis optica spectrum disorder (P16-4.006)
35. Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder
36. High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis
37. Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective
38. Design and Validation of an Expanded Disability Status Scale Model in Multiple Sclerosis
39. Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain
40. Development and pilot phase of a European MS register
41. Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation
42. SARS-CoV-2 Infection in Multiple Sclerosis
43. Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire
44. Quantifying the patients perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire
45. Deciphering Multiple Sclerosis Progression
46. Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder
47. Potential Role of CHI3L1+ Astrocytes in Progression in MS
48. Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.
49. Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis
50. Adding brain volume measures into response criteria in multiple sclerosis: the Río-4 score
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.